Index of reports
> Cases with Sepsis (196)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include sepsis. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 196 Next >>
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24
Patient: male, weighing 121.9 kg (268.2 pounds)
Reactions: Pruritus, Unresponsive To Stimuli, Device Related Infection, Pyrexia, Candidiasis, Abscess Limb, Ventricular Extrasystoles, Metabolic Acidosis, Dyspnoea, Hypotension, Pancytopenia, Tremor, Convulsion, Respiratory Failure, Fungal Infection, Ventricular Tachycardia, Sepsis, Respiratory Arrest, Pulse Absent, Sinus Tachycardia, Hypertension, Feeling Abnormal, Cardiac Arrest, Escherichia Infection, Infusion Related Reaction
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Clolar
Dosage: 74.4 mg, qd
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-06-19
End date: 2012-06-23
Cyclophosphamide
Dosage: daily for 5 days
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-06-19
End date: 2012-06-23
Epinephrine
Dosage: 4 df, unk
Indication: Cardiac Arrest
Start date: 2012-07-14
End date: 2012-07-14
Epinephrine
Dosage: unk
Start date: 2012-07-14
End date: 2012-07-14
Etoposide
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-06-19
End date: 2012-06-23
Oncaspar
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-07-02
End date: 2012-07-02
Vincristine Sulfate
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-07-02
End date: 2012-07-02
Other drugs received by patient: Colace; Bactrim; Stomatitis Mouthwash; Prilosec; Lortab; Cymbalta; Ondansetron; Ambien
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-23
Patient:
Reactions: Confusional State, White Blood Cell Count Decreased, Sepsis, Febrile Neutropenia, Encephalopathy, Platelet Count Decreased, Cystitis, Neutrophil Count Decreased
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Blinded Vorinostat
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Cyclophosphamide
Dosage: 750 mg/m2, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Doxorubicin Hydrochloride
Dosage: 50 mg/m2, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Placebo
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Prednisone TAB
Dosage: 100 mg, qd, on days 3-7
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
End date: 2012-07-29
Rituximab
Dosage: 375 mg/m2, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Simvastatin
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Simvastatin
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Vincristine Sulfate
Dosage: 1.4 mg, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-23
Patient:
Reactions: Confusional State, White Blood Cell Count Decreased, Sepsis, Febrile Neutropenia, Encephalopathy, Platelet Count Decreased, Cystitis, Neutrophil Count Decreased
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Blinded Vorinostat
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Cyclophosphamide
Dosage: 750 mg/m2, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Doxorubicin Hydrochloride
Dosage: 50 mg/m2, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Placebo
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Prednisone TAB
Dosage: 100 mg, qd, on days 3-7
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
End date: 2012-07-29
Rituximab
Dosage: 375 mg/m2, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Simvastatin
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Simvastatin
Dosage: 400 mg, qd, on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-23
End date: 2012-07-27
Vincristine Sulfate
Dosage: 1.4 mg, once, on day 3
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-07-25
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-21
Patient: male, weighing 115.7 kg (254.5 pounds)
Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Cyclophosphamide
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Prednisone TAB
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Remicade
Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
Indication: Rheumatoid Arthritis
Start date: 2001-10-01
End date: 2006-06-29
Vincristine
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Other drugs received by patient: Azulfadine; Lisinopril
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13
Patient:
Reactions: Sepsis, Diffuse Large B-Cell Lymphoma Recurrent, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin
Dosage: days 1 and 5
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: patients on r-chop received 750 mg/m2 on day 1; and acvbp received 1200 mg/m2
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: day 1,patients on r-chop recieved 50 mg/m2; and on acvbp received 75 mg/m2 on day 1
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: days 1 through 5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: day 1, in r-chop regimen
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: day 1 in r-chop regimen
Indication: Diffuse Large B-Cell Lymphoma
Vindesine
Dosage: days 1 and 5
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Fluorodeoxyglucose F 18
Possible Cyclophosphamide side effects in 73 year old female
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-10
Patient: 73 year old female
Reactions: Neutropenic Sepsis, Sepsis
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-04-26
End date: 2012-07-26
Dexamethasone
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-04-26
End date: 2012-07-22
Revlimid
Dosage: 10 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-04-26
End date: 2012-07-01
Possible Cyclophosphamide side effects in 19 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-03
Patient: 19 year old female
Reactions: Dyspnoea, Pancytopenia, Pyrexia, Chronic Myeloid Leukaemia, Multi-Organ Failure, Fatigue, Neoplasm Malignant, Sepsis, Chest Pain
Adverse event resulted in: death
Drug(s) suspected as cause:
Cisplatin
Dosage: 8 consolidation cycles
Indication: Medulloblastoma
Cyclophosphamide
Dosage: 8 consolidation cycles
Indication: Medulloblastoma
Vincristine Sulfate
Dosage: weekly, followed by 8 consolidation cycles
Indication: Medulloblastoma
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-31
Patient:
Reactions: Neutropenic Sepsis, Sepsis, Dyspraxia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: B-Cell Lymphoma
Prednisolone
Dosage: on day 1-5
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in 24 year old female
Reported by a consumer/non-health professional from United States on 2012-07-30
Patient: 24 year old female, weighing 51.0 kg (112.2 pounds)
Reactions: Abdominal Pain, Hyperkalaemia, Disseminated Intravascular Coagulation, Gastrointestinal Necrosis, Acidosis, Nephrolithiasis, Skin Discolouration, Ecchymosis, Clostridial Infection, Emphysema, White Blood Cell Count Decreased, Hypotension, Anaemia, Condition Aggravated, Soft Tissue Infection, Sepsis, Flank Pain, Colitis, Cardiac Arrest, Sinus Tachycardia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: last dose on 16jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Cytarabine
Dosage: last dose:17jun12 route:intra ommya
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Dexamethasone
Dosage: last dose:16jun12
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Doxorubicin HCL
Dosage: last dose:17jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Filgrastim
Dosage: last dose:18jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
End date: 2012-01-01
Leucovorin Calcium
Dosage: last dose :21may12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Mesna
Dosage: last dose:17jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Methotrexate
Dosage: last dose:13jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Methylprednisolone
Dosage: last dose:21may12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Sprycel
Dosage: last dose on 26jun12
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Vincristine Sulfate
Dosage: last dose:17jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-27
Patient:
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Prednisone
Indication: B-Cell Lymphoma
Rituximab
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a physician from Italy on 2012-07-27
Patient:
Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Epirubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Prednisone and Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: 100 mg on days 1-5 for chop and r-chop
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2 on day 1 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in 70 year old male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-19
Patient: 70 year old male
Reactions: Sepsis, Urinary Tract Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Administration route: Oral
Start date: 2012-03-14
End date: 2012-07-06
Dexamethasone
Dosage: 20 milligram
Administration route: Oral
Start date: 2012-03-14
End date: 2012-07-06
Revlimid
Dosage: 25 milligram
Administration route: Oral
Start date: 2012-03-14
End date: 2012-07-06
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-17
Patient:
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Rituxan
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-10
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 300 mg/m2
Cyclophosphamide
Dosage: 250 mg/m2, bid for six doses
Indication: non-Hodgkin's Lymphoma
Cytarabine
Dosage: 100 mg/m2, daily x 5 days
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 30 mg/m2, single
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 60 mg/m2, single
Hydrocortisone Acetate
Dosage: given with methotrexate
Indication: non-Hodgkin's Lymphoma
Hydrocortisone Acetate
Dosage: given with cytarabine
Methotrexate
Dosage: 3000 mg/m2, single
Methotrexate
Dosage: given with hydrocortisone twice x 2
Indication: non-Hodgkin's Lymphoma
Methotrexate
Dosage: 1500 mg/m2, single
Prednisolone
Dosage: 60 mg/m2, daily for 5 days then tapered over 3 days
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 60 mg/m2, daily for 7 days
Rituximab
Dosage: 1875 mg/m2, every 2-4 weeks for 5 total doses
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 2 mg/m2, single
Vincristine
Dosage: 1 mg/m2, single
Indication: non-Hodgkin's Lymphoma
Possible Cyclophosphamide side effects in 18 month old male
Reported by a physician from United States on 2012-07-06
Patient: 18 month old male, weighing 11.4 kg (25.1 pounds)
Reactions: Sepsis, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Dexamethasone Sodium Phosphate
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Dexamethasone Sodium Phosphate
Etoposide
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Lestaurtinib
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Lestaurtinib
Mercaptopurine
Mercaptopurine
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Methotrexate
Vincristine
Vincristine
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Possible Cyclophosphamide side effects in 70 year old male
Reported by a consumer/non-health professional from United Kingdom on 2012-07-05
Patient: 70 year old male
Reactions: Sepsis, Lower Respiratory Tract Infection, Influenza
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2010-11-30
End date: 2011-01-05
Dexamethasone Sodium Phosphate
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2010-11-30
End date: 2011-01-01
Thalidomide
Dosage: 50 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2010-11-30
End date: 2011-01-10
Possible Cyclophosphamide side effects in 37 year old female
Reported by a health professional (non-physician/pharmacist) from Turkey on 2012-06-29
Patient: 37 year old female
Reactions: Bronchopulmonary Aspergillosis, Respiratory Failure, Sepsis, Acute Monocytic Leukaemia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Indication: Breast Cancer
Azacitidine
Azacitidine
Cyclophosphamide
Indication: Breast Cancer
Cytarabine
Indication: Acute Monocytic Leukaemia
Cytarabine
Indication: Acute Monocytic Leukaemia
Fludarabine Phosphate
Indication: Acute Monocytic Leukaemia
Granulocyte Colony-Stimulating Factor
Indication: Acute Monocytic Leukaemia
Idarubicin HCL
Idarubicin HCL
Indication: Acute Monocytic Leukaemia
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29
Patient: female
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (100 mg/m2 on days 1-14 oral)
Administration route: Oral
Indication: Breast Cancer
Fluorouracil
Dosage: (600 mg/m2 ondays 1 and 8 intravenous (not otherwise specified))
Indication: Breast Cancer
Methotrexate
Dosage: (40 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
Indication: Breast Cancer
Possible Cyclophosphamide side effects in female
Reported by a physician from Germany on 2012-06-28
Patient: female
Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Neulasta
Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Dosage: frequency 1 times in 2 week for 5 days
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole
Possible Cyclophosphamide side effects in 16 month old female
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-26
Patient: 16 month old female
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Carboplatin
Dosage: 10 mg/kg daily on days 0
Indication: Brain Neoplasm Malignant
Cisplatin
Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
Indication: Brain Neoplasm Malignant
Cyclophosphamide
Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Etoposide
Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)
Etoposide
Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Ifosfamide
Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
Indication: Brain Neoplasm Malignant
Vincristine
Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
Indication: Brain Neoplasm Malignant
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from Germany on 2012-06-26
Patient: female
Reactions: Syncope, Sepsis, Hypotension, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1493 m
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Rituximab
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Vincristine
Dosage: 3.94 m
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Simvastatin; Levothyroxine; Ramipril; Acyclovir; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Torsemide; Pantoprazole; Nebivolol
Possible Cyclophosphamide side effects in 16 month old female
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-25
Patient: 16 month old female
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Carboplatin
Dosage: 10 mg/kg daily on days 0
Indication: Brain Neoplasm Malignant
Cisplatin
Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
Indication: Brain Neoplasm Malignant
Cyclophosphamide
Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Etoposide
Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Etoposide
Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)
Ifosfamide
Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
Indication: Brain Neoplasm Malignant
Vincristine
Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
Indication: Brain Neoplasm Malignant
Possible Cyclophosphamide side effects in 37 year old female
Reported by a physician from Turkey on 2012-06-22
Patient: 37 year old female
Reactions: Bronchopulmonary Aspergillosis, Respiratory Failure, Acute Myeloid Leukaemia, Sepsis, Febrile Neutropenia, Acute Monocytic Leukaemia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 200 mg/m2 on days 3-6, every 28 days, for 4 cycles
Indication: Breast Cancer
Doxorubicin HCL
Dosage: 40 mg/m2 on day 1, every 28 days, for 4 cycles
Indication: Breast Cancer
Possible Cyclophosphamide side effects in 67 year old male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-06-22
Patient: 67 year old male
Reactions: Sepsis, Pulmonary Oedema, Pyrexia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-26
End date: 2012-05-30
Dexamethasone
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-26
End date: 2012-05-30
Thalidomide
Dosage: 50 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-26
End date: 2012-05-30
Possible Cyclophosphamide side effects in
Reported by a consumer/non-health professional from Germany on 2012-06-21
Patient:
Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous
Adverse event resulted in: death
Drug(s) suspected as cause:
Busulfan
Dosage: 12 mg/kg, unk
Indication: Product Used FOR Unknown Indication
Carboplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cisplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Dosage: 2000 mg/m2, unk
Indication: Product Used FOR Unknown Indication
Doxorubicin Hydrochloride
Dosage: unk
Indication: Product Used FOR Unknown Indication
Etoposide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Fludara
Dosage: 250 mg/m2, unk
Indication: Product Used FOR Unknown Indication
Ifosfamide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Neupogen
Dosage: unk
Indication: Product Used FOR Unknown Indication
Prednisone TAB
Dosage: unk
Indication: Product Used FOR Unknown Indication
Rituxan
Dosage: unk
Indication: Product Used FOR Unknown Indication
Vincristine Sulfate
Dosage: unk
Indication: Product Used FOR Unknown Indication
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Cyclophosphamide side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Methotrexate
Dosage: 3000 mg/m2; administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Methotrexate
Dosage: as part of copadm2 and cym1
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm1
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Possible Cyclophosphamide side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Methotrexate
Dosage: as part of copadm2 and cym1
Methotrexate
Dosage: administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm1
Possible Cyclophosphamide side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm2 and cym1
Methotrexate
Dosage: administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of copadm1
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Page 1 Next >>
|